Altimmune, Inc. (ALT)
4.615
+0.04
(+0.98%)
USD |
NASDAQ |
Feb 13, 14:18
Altimmune Cash from Investing (Quarterly) : -149.32M for Sept. 30, 2025
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| CorMedix, Inc. | -291.32M |
| Actinium Pharmaceuticals, Inc. | 0.00 |
| Aldeyra Therapeutics, Inc. | 25.00M |
| Viking Therapeutics, Inc. | 75.61M |
| Seres Therapeutics, Inc. | -0.008M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -11.90M |
| Cash from Financing (Quarterly) | 39.35M |
| Free Cash Flow | -66.66M |
| Free Cash Flow Per Share (Quarterly) | -0.133 |
| Free Cash Flow to Equity (Quarterly) | -11.95M |
| Free Cash Flow to Firm (Quarterly) | -11.40M |
| Free Cash Flow Yield | -18.19% |